株探米国株
日本語 英語
エドガーで原本を確認する
false000078516100007851612024-08-052024-08-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 5, 2024
Encompass Health Corporation
(Exact name of Registrant as specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-10315 63-0860407
(Commission File Number) (IRS Employer Identification No.)
9001 Liberty Parkway, Birmingham, Alabama 35242
(Address of Principal Executive Offices, Including Zip Code)
(205) 967-7116
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.     Emerging growth company   ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.01 per share EHC New York Stock Exchange


The information contained herein is being furnished pursuant to Item 2.02 of Form 8‑K, “Results of Operations and Financial Condition,” and Item 7.01 of Form 8-K, “Regulation FD Disclosure.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 2.02. Results of Operations and Financial Condition.
On August 5, 2024, Encompass Health Corporation (“Encompass Health” or the “Company”) issued a press release reporting the financial results of the Company for the three and six months ended June 30, 2024. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.
The Company uses “same-store” comparisons to explain the changes in certain performance metrics within its financial statements. Same-store comparisons are calculated based on hospitals open throughout both the full current and prior periods presented. These comparisons include the financial results of market consolidation transactions and capacity expansions (including the addition of satellite and remote hospitals) in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.
ITEM 7.01. Regulation FD Disclosure.
See Item 2.02, “Results of Operations and Financial Condition,” above.
In addition, a copy of the supplemental information which will be discussed during the Company’s earnings call at 10:00 a.m. Eastern Time on Tuesday, August 6, 2024 is attached to this report as Exhibit 99.2 and incorporated herein by reference.
Note Regarding Presentation of Non-GAAP Financial Measures
The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow.
The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”). The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging and equity instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company’s ongoing operating performance. Accordingly, they can complicate comparisons of the Company’s results of operations across periods and comparisons of the Company’s results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States (“GAAP”) as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. The Company reconciles adjusted earnings per share to earnings per share in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.
The leverage ratio referenced therein is defined as the ratio of consolidated total debt to Adjusted EBITDA for the trailing four quarters. The Company believes its leverage ratio and Adjusted EBITDA are measures of its ability to service its debt and its ability to make capital expenditures. Additionally, the leverage ratio is a standard measurement used by investors to gauge the creditworthiness of an institution. The Company’s credit agreement also includes a maximum leverage ratio financial covenant which allows the Company to deduct cash on hand from consolidated total debt. In calculating the leverage ratio under our credit agreement, we are permitted to use pro forma Adjusted EBITDA, the calculation of which includes historical income statement items and pro forma adjustments, subject to certain limitations, resulting from (1) dispositions and repayments or incurrence of debt and (2) investments, acquisitions, mergers, amalgamations, consolidations and other operational changes to the extent such items or effects are not yet reflected in our trailing four-quarter financial statements. The Company reconciles Adjusted EBITDA to net cash provided by operating activities and net income in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2.


The Company uses Adjusted EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company’s credit agreement, which is discussed in more detail in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Liquidity and Capital Resources,” and Note 10, Long-term Debt, to the consolidated financial statements included in its Annual Report on Form 10‑K for the year ended December 31, 2023 (the “2023 Form 10‑K”). These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under the credit agreement—its interest coverage ratio and its leverage ratio—could result in the Company’s lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders, which would have some cost to the Company, and such relief might be on terms less favorable to those in the Company’s existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the Company’s assessment of its liquidity.
In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as “Adjusted Consolidated EBITDA,” allows the Company to add back to consolidated net income interest expense, income taxes, and depreciation and amortization and then add back to consolidated net income (1) all unusual or nonrecurring items reducing consolidated net income (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3) non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4) share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment of debt and acquisitions, and (7) any restructuring charges and certain pro-forma cost savings and synergies related to transactions and initiatives, which in the aggregate are not in excess of 25% of Adjusted Consolidated EBITDA. The Company also subtracts from consolidated net income all unusual or nonrecurring items to the extent they increase consolidated net income.
The calculation of Adjusted EBITDA under the credit agreement does not require us to deduct net income attributable to noncontrolling interests or gains on fair value adjustments of hedging and equity instruments, disposal of assets, and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or unusual or nonrecurring cash expenditures in excess of $10 million. These items and amounts, in addition to the items falling within the credit agreement’s “unusual or nonrecurring” classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, the Company's ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.
Adjusted EBITDA is not a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies, to the consolidated financial statements accompanying the 2023 Form 10‑K.
The Company also uses adjusted free cash flow as an analytical indicator to assess its performance. Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company’s capacity to reduce debt, pursue development activities, and return capital to its common stockholders. The calculation of adjusted free cash flow and a reconciliation of net cash provided by operating activities to adjusted free cash flow are included in the press release attached as Exhibit 99.1 and the supplemental information attached as Exhibit 99.2. This measure is not a defined measure of financial performance under GAAP and should not be considered as an alternative to net cash provided by operating activities. The Company's definition of adjusted free cash flow is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, distributions to noncontrolling interests, and certain items deemed to be non-indicative of ongoing operating performance. Common stock dividends are not included in the calculation of adjusted free cash flow. The Company’s definition of adjusted free cash flow is limited and does not represent residual cash flows available for discretionary spending. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of cash flows included in the 2023 Form 10‑K, the condensed consolidated statements of cash flows included in the Company's quarterly report on Form 10-Q for the quarterly period ended June 30, 2024 (the "June 2024 Form 10-Q"), when filed, and in the press release attached as Exhibit 99.1 for the GAAP measures of cash flows from operating, investing, and financing activities.


Forward-Looking Statements
The information contained in the press release and supplemental information includes certain estimates, projections, and other forward-looking statements that involve known and unknown risks and relate to, among other things, future events, the business model, strategy, outlook and guidance, growth targets, labor cost trends, financial plans, dividend strategies or payments, effective income tax rates, plans to repurchase its debt or equity securities, future financial performance, projected business results, ability to return value to its shareholders, projected capital expenditures and development plans, leverage ratio, guidance considerations, and the impact of future legislation or regulation. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “targets,” “potential,” or “continue” or the negative of these terms or other comparable terminology. These estimates, projections, and other forward-looking statements are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual results, and those differences may be material.
There can be no assurance that any estimates, projections, or forward-looking statements will be realized.
All such estimates, projections, and forward-looking statements speak only as of the date hereof. The Company undertakes no duty to publicly update or revise that information.
You are cautioned not to place undue reliance on the estimates, projections, and other forward-looking statements in this report, the press release, and supplemental information as they are based on current expectations and general assumptions and are subject to various risks, uncertainties, and other factors, including those set forth in the attached press release and in the 2023 Form 10‑K, the June 2024 Form 10-Q when filed, and in other documents the Company previously filed with the SEC, many of which are beyond the Company’s control. These factors may cause actual results to differ materially from the views, beliefs, and estimates expressed herein.
ITEM 9.01. Financial Statements and Exhibits.
(d)    Exhibits.
Exhibit Number Description
104 Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
ENCOMPASS HEALTH CORPORATION
By:
/S/   DOUGLAS E. COLTHARP
Name: Douglas E. Coltharp
Title: Executive Vice President and Chief Financial Officer
Dated: August 5, 2024

EX-99.1 2 ehcearningsrelease63024.htm EX-99.1 Document
Exhibit 99.1

encompasshealthnewlogoa15a.jpg
Media Contact August 5, 2024
Polly Manuel, 205 969-4532
polly.manuel@encompasshealth.com
Investor Relations Contact
Mark Miller, 205 970-5860
mark.miller@encompasshealth.com

Encompass Health reports results for second quarter 2024

Increases full-year guidance

BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the second quarter ended June 30, 2024.
Summary results
Growth
Q2 2024 Q2 2023 Dollars Percent
(In Millions, Except Per Share Data)
Net operating revenue $ 1,301.2  $ 1,187.1  $ 114.1  9.6  %
Income from continuing operations attributable to Encompass Health per diluted share
 1.13  0.91  0.22  24.2  %
Adjusted earnings per share 1.11  0.95  0.16  16.8  %
Cash flows provided by operating activities
 217.4  206.7  10.7  5.2  %
Adjusted EBITDA 271.8  249.6  22.2  8.9  %
Adjusted free cash flow 142.5  124.2  18.3  14.7  %
(Actual Amounts)
Discharges 60,833 57,011 6.7  %
   Same-store discharge growth 4.8  %
Net patient revenue per discharge $ 20,803  $ 20,387  2.0  %
See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.
“We are pleased with our second quarter performance as strong discharge growth facilitated an increase of 9.6% in revenue and 8.9% in Adjusted EBITDA,” said President and Chief Executive Officer of Encompass Health Mark Tarr. “During the quarter we added 194 beds to our capacity and made continued progress across our key operating initiatives. We also resumed activity under our share repurchase authorization. We remain highly-optimistic about the long-term prospects of our business.”


1

•Revenue growth of 9.6% resulted primarily from discharge growth of 6.7%, including same-store growth of 4.8%. Net revenue per discharge grew 2.0%.
•Cash flows provided by operating activities increased 5.2% to $217.4 million, primarily due to an increase in net income partly offset by higher cash tax payments.

•Adjusted EBITDA increased 8.9%, primarily from increased revenue.


2024 Guidance
The Company increased its full-year guidance as follows:
Full-Year 2024 Guidance
Previous Guidance Updated Guidance
(In Millions, Except Per Share Data)
Net operating revenue $5,250 to $5,325 $5,275 to $5,350
Adjusted EBITDA $1,030 to $1,065 $1,040 to $1,075
Adjusted earnings per share from continuing operations attributable to Encompass Health $3.86 to $4.11 $3.97 to $4.22
For considerations regarding the Company’s 2024 guidance, see the supplemental information posted on the Company’s website at http://investor.encompasshealth.com. See also the “Other information” section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.
Earnings conference call and webcast
The Company will host an investor conference call at 10:00 a.m. Eastern Time on Tuesday, August 6, 2024 to discuss its results for the second quarter of 2024. For reference during the call, the Company will post certain supplemental information at http://investor.encompasshealth.com.
The conference call may be accessed by dialing 800 579-2543 and giving the conference ID EHCQ224. International callers should dial 785 424-1699 and give the same conference ID. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at http://investor.encompasshealth.com by clicking on an available link.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 164 hospitals in 38 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World’s Most Admired Companies and Becker’s Hospital Review’s 150 Top Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.

Other information
The information in this press release is summarized and should be read in conjunction with the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “June 2024 Form 10-Q”), when filed, as well as the Company’s Current Report on Form 8-K filed on August 5, 2024 (the “Q2 Earnings Form 8-K”), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at http://investor.encompasshealth.com for reference during its August 6, 2024 earnings call.
2

The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q2 Earnings Form 8-K. Readers are encouraged to review the “Note Regarding Presentation of Non-GAAP Financial Measures” included in the Q2 Earnings Form 8-K which provides further explanation and disclosure regarding the Company’s use of these non-GAAP financial measures.
Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company’s results computed in accordance with GAAP.
However, the following reasonably estimable GAAP measures for 2024 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:
•Interest expense and amortization of debt discounts and fees - approximately $140 million
•Amortization of debt-related items - approximately $10 million
The Q2 Earnings Form 8-K and, when filed, the June 2024 Form 10-Q can be found on the Company’s website at http://investor.encompasshealth.com and the SEC's website at www.sec.gov.
3
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended June 30, Six Months Ended June 30,
  2024 2023 2024 2023
(In Millions, Except Per Share Data)
Net operating revenues $ 1,301.2  $ 1,187.1  $ 2,617.2  $ 2,347.5 
Operating expenses:
Salaries and benefits 700.5  636.2  1,412.1  1,265.2 
Other operating expenses 189.9  172.7  393.8  350.6 
Occupancy costs 14.2  14.3  28.2  28.1 
Supplies 57.6  52.0  116.1  105.8 
General and administrative expenses 50.5  55.4  100.7  98.8 
Depreciation and amortization 72.9  72.6  143.2  136.5 
Total operating expenses 1,085.6  1,003.2  2,194.1  1,985.0 
Interest expense and amortization of debt discounts and fees 34.3  36.3  69.5  72.7 
Other income (3.3) (2.7) (8.7) (6.3)
Equity in net income of nonconsolidated affiliates (1.4) (0.9) (2.1) (1.3)
Income from continuing operations before income tax expense 186.0  151.2  364.4  297.4 
Provision for income tax expense 38.3  32.8  76.6  64.7 
Income from continuing operations 147.7  118.4  287.8  232.7 
Loss from discontinued operations, net of tax (1.2) (1.2) (2.5) (2.2)
Net and comprehensive income 146.5  117.2  285.3  230.5 
Less: Net and comprehensive income attributable to noncontrolling interests (32.4) (25.8) (58.7) (51.4)
Net and comprehensive income attributable to Encompass Health $ 114.1  $ 91.4  $ 226.6  $ 179.1 
Weighted average common shares outstanding:    
Basic 99.9  99.5  99.9  99.5 
Diluted 102.0  101.1  102.1  101.0 
Earnings per common share:
Basic earnings per share attributable to Encompass Health common shareholders:
      
Continuing operations
 $ 1.14  $ 0.92  $ 2.28  $ 1.81 
Discontinued operations
 (0.01) (0.01) (0.03) (0.02)
Net income
 $ 1.13  $ 0.91  $ 2.25  $ 1.79 
Diluted earnings per share attributable to Encompass Health common shareholders:
Continuing operations
 $ 1.13  $ 0.91  $ 2.24  $ 1.79 
Discontinued operations
 (0.01) (0.01) (0.02) (0.02)
Net income
 $ 1.12  $ 0.90  $ 2.22  $ 1.77 
Amounts attributable to Encompass Health common shareholders:  
Income from continuing operations $ 115.3  $ 92.6  $ 229.1  $ 181.3 
Loss from discontinued operations, net of tax (1.2) (1.2) (2.5) (2.2)
Net income attributable to Encompass Health $ 114.1  $ 91.4  $ 226.6  $ 179.1 
4
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)
June 30, 2024 December 31, 2023
  (In Millions)
Assets    
Current assets:    
Cash and cash equivalents $ 154.4  $ 69.1 
Restricted cash 27.7  35.1 
Accounts receivable 589.7  611.6 
Other current assets 166.3  126.0 
Total current assets 938.1  841.8 
Property and equipment, net 3,438.9  3,301.0 
Operating lease right-of-use assets 216.3  208.5 
Goodwill 1,284.0  1,281.3 
Intangible assets, net 303.0  278.2 
Other long-term assets 208.4  191.6 
Total assets $ 6,388.7  $ 6,102.4 
Liabilities and Shareholders’ Equity
Current liabilities:    
Current portion of long-term debt $ 32.5  $ 24.8 
Current operating lease liabilities 26.6  24.1 
Accounts payable 164.2  170.0 
Accrued expenses and other current liabilities 471.2  437.5 
Total current liabilities 694.5  656.4 
Long-term debt, net of current portion 2,684.1  2,687.8 
Long-term operating lease liabilities 202.0  196.1 
Deferred income tax liabilities 91.2  87.0 
Other long-term liabilities 186.9  177.9 
Total liabilities 3,858.7  3,805.2 
Commitments and contingencies
Redeemable noncontrolling interests 48.6  42.0 
Shareholders’ equity:    
Encompass Health shareholders’ equity 1,839.4  1,647.5 
Noncontrolling interests 642.0  607.7 
Total shareholders’ equity 2,481.4  2,255.2 
Total liabilities and shareholders’ equity $ 6,388.7  $ 6,102.4 
5
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited)
  Six Months Ended June 30,
  2024 2023
  (In Millions)
Cash flows from operating activities:    
Net income $ 285.3  $ 230.5 
Loss from discontinued operations, net of tax 2.5  2.2 
Adjustments to reconcile net income to net cash provided by operating activities—    
Depreciation and amortization 143.2  136.5 
Stock-based compensation 22.9  23.5 
Deferred tax expense 4.2  0.3 
Other, net 14.2  3.1 
Change in assets and liabilities, net of acquisitions—    
Accounts receivable 0.9  11.5 
Other assets (48.4) (8.4)
Accounts payable 1.8  4.0 
Other liabilities 32.3  34.3 
Net cash used in operating activities of discontinued operations (2.7) (2.9)
Total adjustments 168.4  201.9 
Net cash provided by operating activities 456.2  434.6 
Cash flows from investing activities:
Purchases of property, equipment, and intangible assets (296.3) (221.7)
Proceeds from sale of restricted investments 17.0  1.0 
Other, net (8.8) (11.8)
Net cash used in investing activities (288.1) (232.5)
Cash flows from financing activities:    
Principal borrowings on notes —  20.0 
Principal payments on debt, including pre-payments (2.4) (5.7)
Borrowings on revolving credit facility 50.0  60.0 
Payments on revolving credit facility (50.0) (115.0)
Principal payments under finance lease obligations (10.7) (9.5)
Taxes paid on behalf of employees for shares withheld (12.1) (7.7)
Contributions from noncontrolling interests of consolidated affiliates 33.3  46.3 
Dividends paid on common stock (30.8) (30.5)
Distributions paid to noncontrolling interests of consolidated affiliates (52.5) (59.4)
Repurchases of common stock, including fees and expenses (16.8) — 
Other, net 1.8  — 
Net cash used in financing activities (90.2) (101.5)
Increase in cash, cash equivalents, and restricted cash 77.9  100.6 
Cash, cash equivalents, and restricted cash at beginning of period 104.2  53.4 
Cash, cash equivalents, and restricted cash at end of period $ 182.1  $ 154.0 
6
Encompass Health Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Continued)
(Unaudited)
Six Months Ended June 30,
2024 2023
(In Millions)
Reconciliation of Cash, Cash Equivalents, and Restricted Cash
Cash and cash equivalents at beginning of period
 $ 69.1  $ 21.8 
Restricted cash at beginning of period
 35.1  31.6 
Cash, cash equivalents, and restricted cash at beginning of period
 $ 104.2  $ 53.4 
Cash and cash equivalents at end of period
 $ 154.4  $ 117.5 
Restricted cash at end of period
 27.7  36.5 
Cash, cash equivalents, and restricted cash at end of period
 $ 182.1  $ 154.0 
7
Encompass Health Corporation and Subsidiaries
Supplemental Information
Earnings Per Share
Three Months Ended June 30, Six Months Ended June 30,
2024 2023 2024 2023
(In Millions, Except Per Share Data)
Adjusted EBITDA $ 271.8  $ 249.6  $ 544.8  $ 478.6 
Depreciation and amortization
 (72.9) (72.6) (143.2) (136.5)
Interest expense and amortization of debt discounts and fees
 (34.3) (36.3) (69.5) (72.7)
Stock-based compensation (13.6) (15.6) (22.9) (23.5)
Gain (loss) on disposal or impairment of assets 3.0  (0.8) (10.7) (1.5)
154.0  124.3  298.5  244.4 
Items not indicative of ongoing operating performance:
State regulatory change impact on noncontrolling interests —  2.2  —  2.2 
Change in fair market value of equity securities
 (0.4) (1.1) (0.1) (0.6)
Asset impairment impact on noncontrolling interests —  —  7.3  — 
Pre-tax income 153.6  125.4  305.7  246.0 
Income tax expense
 (38.3) (32.8) (76.6) (64.7)
Income from continuing operations (1)
 $ 115.3  $ 92.6  $ 229.1  $ 181.3 
Basic shares 99.9  99.5  99.9  99.5 
Diluted shares 102.0  101.1  102.1  101.0 
Basic earnings per share (1)
 $ 1.14  $ 0.92  $ 2.28  $ 1.81 
Diluted earnings per share (1)
 $ 1.13  $ 0.91  $ 2.24  $ 1.79 
(1)Income from continuing operations attributable to Encompass Health
8
Encompass Health Corporation and Subsidiaries
Supplemental Information
Adjusted Earnings Per Share

Q2 6 Months
2024 2023 2024 2023
Earnings per share, as reported $ 1.13  $ 0.91  $ 2.24  $ 1.79 
Adjustments, net of tax:
Asset impairment impact —  —  0.02  — 
Income tax adjustments
 (0.02) —  (0.03) — 
State regulatory change impact —  0.03  —  0.03 
Change in fair market value of equity securities
 —  0.01  —  — 
Adjusted earnings per share*
 $ 1.11  $ 0.95  $ 2.23  $ 1.83 
*    Adjusted EPS may not sum due to rounding.

9
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

Three Months Ended June 30, Six Months Ended June 30,
2024 2023 2024 2023
(In Millions)
Net cash provided by operating activities
 $ 217.4  $ 206.7  $ 456.2  $ 434.6 
Interest expense and amortization of debt discounts and fees
 34.3  36.3  69.5  72.7 
(Loss) gain on sale of investments, excluding impairments (0.1) 0.1  1.2  1.8 
Equity in net income of nonconsolidated affiliates
 1.4  0.9  2.1  1.3 
Net income attributable to noncontrolling interests in continuing operations
 (32.4) (25.8) (58.7) (51.4)
Amortization of debt-related items
 (2.5) (2.4) (4.9) (4.7)
Distributions from nonconsolidated affiliates
 (1.2) (0.1) (2.0) (0.2)
Current portion of income tax expense 40.6  36.5  72.4  64.4 
Change in assets and liabilities 11.8  (3.5) 13.4  (41.4)
Cash used in operating activities of discontinued operations 2.0  1.6  2.7  2.9 
State regulatory change impact on noncontrolling interests —  (2.2) —  (2.2)
Asset impairment impact on noncontrolling interests —  —  (7.3) — 
Change in fair market value of equity securities 0.4  1.1  0.1  0.6 
Other 0.1  0.4  0.1  0.2 
Adjusted EBITDA $ 271.8  $ 249.6  $ 544.8  $ 478.6 

10
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share
For the Three Months Ended June 30, 2024
Adjustments
As Reported Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted
(In Millions, Except Per Share Amounts)
Adjusted EBITDA* $ 271.8  $ —  $ —  $ 271.8 
Depreciation and amortization (72.9) —  —  (72.9)
Interest expense and amortization of debt discounts and fees
 (34.3) —  —  (34.3)
Stock-based compensation (13.6) —  —  (13.6)
Gain on disposal or impairment of assets 3.0  —  —  3.0 
Change in fair market value of equity securities
 (0.4) —  0.4  — 
Income from continuing operations before income tax expense
 153.6  —  0.4  154.0 
Provision for income tax expense (38.3) (2.4) (0.1) (40.8)
Income from continuing operations attributable to Encompass Health
 $ 115.3  $ (2.4) $ 0.3  $ 113.2 
Diluted earnings per share from continuing operations** $ 1.13  $ (0.02) $ —  $ 1.11 
Diluted shares used in calculation 102.0 

*    Reconciliation to GAAP provided on page 10
**    Adjusted EPS may not sum across due to rounding.
11
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share
For the Three Months Ended June 30, 2023
Adjustments
As Reported State Regulatory Change Impact Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted
(In Millions, Except Per Share Amounts)
Adjusted EBITDA* $ 249.6  $ —  $ —  $ —  $ 249.6 
Depreciation and amortization (72.6) 6.1  —  —  (66.5)
Interest expense and amortization of debt discounts and fees
 (36.3) —  —  —  (36.3)
Stock-based compensation (15.6) —  —  —  (15.6)
Loss on disposal or impairment of assets (0.8) —  —  —  (0.8)
State regulatory change impact on noncontrolling interests 2.2  (2.2) —  —  — 
Change in fair market value of equity securities
 (1.1) —  —  1.1  — 
Income from continuing operations before income tax expense
 125.4  3.9  —  1.1  130.4 
Provision for income tax expense (32.8) (1.0) 0.1  (0.3) (34.0)
Income from continuing operations attributable to Encompass Health
 $ 92.6  $ 2.9  $ 0.1  $ 0.8  $ 96.4 
Diluted earnings per share from continuing operations**
 $ 0.91  $ 0.03  $ —  $ 0.01  $ 0.95 
Diluted shares used in calculation 101.1 

*    Reconciliation to GAAP provided on page 10
**    Adjusted EPS may not sum across due to rounding.
12
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share
For the Six Months Ended June 30, 2024
Adjustments
As Reported Asset Impairment Impact Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted
(In Millions, Except Per Share Amounts)
Adjusted EBITDA* $ 544.8  $ —  $ —  $ —  $ 544.8 
Depreciation and amortization (143.2) —  —  —  (143.2)
Interest expense and amortization of debt discounts and fees
 (69.5) —  —  —  (69.5)
Stock-based compensation (22.9) —  —  —  (22.9)
Loss on disposal or impairment of assets (10.7) 10.4  —  —  (0.3)
Change in fair market value of equity securities
 (0.1) —  —  0.1  — 
Asset impairment impact on noncontrolling interests 7.3  (7.3) —  —  — 
Income from continuing operations before income tax expense
 305.7  3.1  —  0.1  308.9 
Provision for income tax expense (76.6) (1.3) (3.0) —  (80.9)
Income from continuing operations attributable to Encompass Health
 $ 229.1  $ 1.8  $ (3.0) $ 0.1  $ 228.0 
Diluted earnings per share from continuing operations** $ 2.24  $ 0.02  $ (0.03) $ —  $ 2.23 
Diluted shares used in calculation 102.1 
*    Reconciliation to GAAP provided on page 10
**    Adjusted EPS may not sum across due to rounding.
13
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share
For the Six Months Ended June 30, 2023
Adjustments
As Reported State Regulatory Change Impact Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted
(In Millions, Except Per Share Amounts)
Adjusted EBITDA* $ 478.6  $ —  $ —  $ —  $ 478.6 
Depreciation and amortization (136.5) 6.1  —  —  (130.4)
Interest expense and amortization of debt discounts and fees
 (72.7) —  —  —  (72.7)
Stock-based compensation (23.5) —  —  —  (23.5)
Loss on disposal or impairment of assets (1.5) —  —  —  (1.5)
State regulatory change impact on noncontrolling interests 2.2  (2.2) —  —  — 
Change in fair market value of equity securities
 (0.6) —  —  0.6  — 
Income from continuing operations before income tax expense
 246.0  3.9  —  0.6  250.5 
Provision for income tax expense (64.7) (1.0) 0.4  (0.2) (65.5)
Income from continuing operations attributable to Encompass Health
 $ 181.3  $ 2.9  $ 0.4  $ 0.4  $ 185.0 
Diluted earnings per share from continuing operations**
 $ 1.79  $ 0.03  $ —  $ —  $ 1.83 
Diluted shares used in calculation 101.0 
*    Reconciliation to GAAP provided on page 10
**    Adjusted EPS may not sum across due to rounding.
14
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Income to Adjusted EBITDA

  Three Months Ended June 30, Six Months Ended June 30,
  2024 2023 2024 2023
(In Millions)
Net income $ 146.5  $ 117.2  $ 285.3  $ 230.5 
Loss from discontinued operations, net of tax, attributable to Encompass Health 1.2  1.2  2.5  2.2 
Net income attributable to noncontrolling interests included in continuing operations (32.4) (25.8) (58.7) (51.4)
Provision for income tax expense 38.3  32.8  76.6  64.7 
Interest expense and amortization of debt discounts and fees
 34.3  36.3  69.5  72.7 
Depreciation and amortization 72.9  72.6  143.2  136.5 
(Gain) loss on disposal or impairment of assets (3.0) 0.8  10.7  1.5 
Stock-based compensation 13.6  15.6  22.9  23.5 
State regulatory change impact on noncontrolling interests —  (2.2) —  (2.2)
Change in fair market value of equity securities 0.4  1.1  0.1  0.6 
Asset impairment impact on noncontrolling interests —  —  (7.3) — 
Adjusted EBITDA $ 271.8  $ 249.6  $ 544.8  $ 478.6 


15
Encompass Health Corporation and Subsidiaries
Supplemental Information
Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow
Three Months Ended June 30, Six Months Ended June 30,
2024 2023 2024 2023
(In Millions)
Net cash provided by operating activities $ 217.4  $ 206.7  $ 456.2  $ 434.6 
Impact of discontinued operations 2.0  1.6  2.7  2.9 
Net cash provided by operating activities of continuing operations
 219.4  208.3  458.9  437.5 
Capital expenditures for maintenance (48.9) (56.7) (87.6) (94.5)
Distributions paid to noncontrolling interests of consolidated affiliates
 (27.8) (27.6) (52.5) (59.4)
Items not indicative of ongoing operating performance:
Transaction costs and related liabilities (0.2) 0.2  (8.7) (0.7)
Adjusted free cash flow $ 142.5  $ 124.2  $ 310.1  $ 282.9 
For the three months ended June 30, 2024, net cash used in investing activities was $158.4 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended June 30, 2024 was $49.6 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and repurchases of common stock partially offset by contributions from noncontrolling interests of consolidated affiliates.
For the three months ended June 30, 2023, net cash used in investing activities was $128.5 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended June 30, 2023 was $43.5 million and resulted primarily from net debt payments, distributions paid to noncontrolling interests of consolidated affiliates, and cash dividends paid on common stock partially offset by contributions from noncontrolling interests of consolidated affiliates.
For the six months ended June 30, 2024, net cash used in investing activities was $288.1 million and resulted primarily from capital expenditures. Net cash used in financing activities during the six months ended June 30, 2024 was $90.2 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, cash dividends paid on common stock, and repurchases of common stock partially offset by contributions from noncontrolling interests of consolidated affiliates.
For the six months ended June 30, 2023, net cash used in investing activities was $232.5 million and resulted primarily from capital expenditures. Net cash used in financing activities during the six months ended June 30, 2023 was $101.5 million and resulted primarily from net debt payments, distributions paid to noncontrolling interests of consolidated affiliates, and cash dividends paid on common stock partially offset by contributions from noncontrolling interests of consolidated affiliates.
16
Encompass Health Corporation and Subsidiaries
Forward-Looking Statements
Statements contained in this press release and the supplemental information which are not historical facts, such as those relating to the business, strategy, outlook, growth targets and guidance considerations, dividend strategies, effective income tax rates, cost trends, legislative and regulatory developments or their impacts, financial guidance, ability to return value to shareholders, projected capital expenditures, acquisition opportunities, development projects, addressable market size, other balance sheet and cash flow plans, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, an infectious disease outbreak, including the speed, depth, geographic reach and duration of its spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; Encompass Health's infectious disease prevention and control efforts; the demand for Encompass Health’s services, including based on any downturns in the economy, consumer confidence, or the capital markets; the price of Encompass Health's common stock as it affects Encompass Health's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; any adverse effects on Encompass Health's stock price resulting from the integration of acquired operations; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or its vendors' or partners’ information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability as well as unforeseen issues, if any, related to integration of acquired systems; the ability to successfully integrate acquired operations, including realization of anticipated tax benefits, revenues, and cost savings, minimizing the negative impact on margins arising from the changes in staffing and other operating practices, and avoidance of unforeseen exposure to liabilities; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; Encompass Health’s ability to realize construction cost savings from prefabrication of hospitals; increases in Medicare audit activity, including increased use of sampling and extrapolation, resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction and Encompass Health's ability to adapt operations to those changes, including in connection with the CMS inpatient rehabilitation review choice demonstration project; competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and retain favorable arrangements with third-party payors; Encompass Health's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis; Encompass Health's ability to adapt to changes in the healthcare delivery system, including value-based purchasing and involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, which may be worsened by infectious disease outbreaks, and the impact on Encompass Health's labor expenses from potential union activity, staffing shortages, and competitive compensation practices; general conditions in the economy and capital markets, including any
17
Encompass Health Corporation and Subsidiaries
Forward-Looking Statements
instability or uncertainty related to armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; the increase in the cost of, or the decrease in the availability of, necessary supplies, such as personal protective equipment; the increase in the costs of defending and insuring against alleged professional liability claims, and Encompass Health's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10‑K for the year ended December 31, 2023 and Form 10-Q for the quarters ended March 31, 2024, and June 30, 2024, when filed.
18
EX-99.2 3 ehcq22024earningsslides_.htm EX-99.2 ehcq22024earningsslides_
2024 Second Quarter Earnings Call August 6, 2024 Supplemental information

 
Encompass Health 2 The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect Encompass Health’s current outlook, views and plans with respect to future events, including the business outlook, guidance and growth targets, labor availability and costs, legislative and regulatory developments, strategy, capital expenditures, acquisition and other development activities, such as the de novo pipeline, costs, growth and timelines, operational initiatives, dividend strategies, leverage, repurchases of securities, outstanding shares of common stock, effective tax rates, financial performance, financial assumptions and considerations, balance sheet and cash flow plans, market barriers to entry, and addressable market size. These estimates, projections and other forward-looking information are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material. There can be no assurance any estimates, projections or forward-looking information will be realized. All such estimates, projections and forward-looking information speak only as of the date hereof. Encompass Health undertakes no duty to publicly update or revise the information contained herein. You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the earnings release attached as Exhibit 99.1 to the Company’s Form 8-K dated August 5, 2024 (the “Q2 Earnings Release Form 8-K”), the Form 10-K for the year ended December 31, 2023, the Form 10-Q for the quarter ended March 31, 2024, the Form 10-Q for the quarter ended June 30, 2024, when filed, and in other documents Encompass Health previously filed with the SEC, many of which are beyond Encompass Health’s control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein. Note regarding presentation of non-GAAP financial measures The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, leverage ratios, adjusted earnings per share, and adjusted free cash flow. Schedules are attached that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. The Q2 Earnings Release Form 8-K provides further explanation and disclosure regarding Encompass Health’s use of non-GAAP financial measures and should be read in conjunction with this supplemental information. Forward-looking statements

 
Encompass Health 3 Q2 2024 Financial summary ............................................................................................................................................. 4 Key takeaways ...................................................................................................................................................................... 5 Revenue ................................................................................................................................................................................. 6 Adjusted EBITDA .................................................................................................................................................................. 7 Earnings per share ............................................................................................................................................................... 8-9 Adjusted free cash flow ..................................................................................................................................................... 10 2024 Guidance and guidance considerations ............................................................................................................... 11-12 Adjusted free cash flow assumptions ............................................................................................................................. 13 Uses of free cash flow ........................................................................................................................................................ 14 Appendix Map of locations ................................................................................................................................................................... 16 Growth targets, fundamentals and value drivers ........................................................................................................ 17 Development activity ......................................................................................................................................................... 18 Debt maturity profile and schedule ................................................................................................................................ 19-20 New-store/same-store growth .......................................................................................................................................... 21 Payment sources .................................................................................................................................................................. 22 Operational metrics ............................................................................................................................................................ 23 Share information ................................................................................................................................................................ 24 Reconciliations to GAAP ..................................................................................................................................................... 25-32 End notes ............................................................................................................................................................................... 33-34 Table of contents

 
Encompass Health 4 Q2 2024 Financial summary Q2 6 Months ($ in millions, except per share data) 2024 2023 % △ 2024 2023 % △ Encompass Health Net operating revenue $ 1,301.2 $ 1,187.1 9.6 % $ 2,617.2 $ 2,347.5 11.5 % Adjusted EBITDA $ 271.8 $ 249.6 8.9 % $ 544.8 $ 478.6 13.8 % Adjusted EPS $ 1.11 $ 0.95 16.8 % $ 2.23 $ 1.83 21.9 % Adjusted free cash flow $ 142.5 $ 124.2 14.7 % $ 310.1 $ 282.9 9.6 % Reconciliations to GAAP provided on pages 25-32.

 
Encompass Health 5 Q2 2024 Key takeaways u Revenue Ÿ Net operating revenue growth of 9.6% ü Discharge growth of 6.7% (4.8% same store) u Adjusted EBITDA Ÿ Adjusted EBITDA growth of 8.9% u Balance sheet Ÿ Net leverage of 2.5x u Capacity additions Ÿ Opened 3 de novo hospitals with a total of 130 beds Ÿ Opened 1 40-bed satellite hospital Ÿ Added 24 beds to existing hospitals u Shareholder distributions Ÿ Repurchased 198,708 shares of common stock for $16.8 million Ÿ Paid a $0.15 per share cash dividend in April 2024 Ÿ Declared a $0.15 per share cash dividend in May 2024 (paid in July 2024) u Events subsequent Ÿ Expanded Piedmont joint venture with the addition of our existing Augusta, Georgia hospital Ÿ Issued notice of redemption for $150 million of 5.75% Senior Notes due 2025 with a settlement date of August 15, 2024 Ÿ Declared a $0.17 per share cash dividend in July 2024 (to be paid in October 2024) Ÿ Increased common stock repurchase authorization to $500 million in July 2024(1) Reconciliations to GAAP provided on pages 25-32. Refer to pages 33-34 for end notes.

 
Encompass Health 6 Revenue Q2 Q2 % Change* ($ in millions) 2024 2023 Net operating revenue: Inpatient $ 1,265.5 $ 1,162.3 8.9% Outpatient and other 35.7 24.8 44.0% Total revenue $ 1,301.2 $ 1,187.1 9.6% (Actual Amounts) Discharges 60,833 57,011 6.7% New-store discharge growth 1.9% Same-store discharge growth 4.8% Net patient revenue per discharge $ 20,803 $ 20,387 2.0% Revenue reserves related to bad debt as a percent of revenue 2.9 % 1.9 % 100 bps u Outpatient and other revenue includes a $10.3 million increase in provider tax revenues. u Bad debt as a percent of revenue increased 100 basis points, primarily attributable to: Ÿ Increase in medical necessity claim review audits Ÿ Reversal of Supplemental Medical Review Contractor (“SMRC”) audit reserves in Q2-23 *Except for Revenue reserves related to bad debt as a percent of revenue, which is increase (decrease)

 
Encompass Health 7 Adjusted EBITDA(2) Q2 % of Revenue Q2 % of Revenue($ in millions) 2024 2023 Net operating revenue $ 1,301.2 $ 1,187.1 Operating expenses: Salaries and benefits (700.5) 53.8 % (636.2) 53.6 % Other operating expenses(a) (192.9) 14.8 % (171.9) 14.5 % Supplies (57.6) 4.4 % (52.0) 4.4 % Occupancy costs (14.2) 1.1 % (14.3) 1.2 % Hospital operating expenses (264.7) 20.3 % (238.2) 20.1 % General and administrative expenses(b) (36.3) 2.8 % (38.3) 3.2 % Other income(c) 3.1 2.3 Equity in nonconsolidated affiliates 1.4 0.9 Noncontrolling interests in continuing operations(d) (32.4) (28.0) Adjusted EBITDA $ 271.8 $ 249.6 Percent change 8.9 % Q2 Q2 ($ in millions) 2024 2023 In arriving at Adjusted EBITDA, the following were excluded: (a) (Gain) loss on disposal or impairment of assets $ (3.0) $ 0.8 (b) Stock-based compensation and the change in fair market value of the non- qualified deferred comp plan $ 14.2 $ 17.1 (c) Change in fair market value of equity securities and the non-qualified deferred comp plan $ (0.2) $ (0.4) (d) State regulatory change impact on noncontrolling interests(3) $ — $ (2.2) Reconciliations to GAAP provided on pages 25-32. Refer to pages 33-34 for end notes. u Adjusted EBITDA includes a $4.9 million increase in net provider tax revenues.

 
Encompass Health 8 Earnings per share - as reported Q2 6 Months ($ in millions, except per share data) 2024 2023 2024 2023 Adjusted EBITDA $ 271.8 $ 249.6 $ 544.8 $ 478.6 Depreciation and amortization(3) (72.9) (72.6) (143.2) (136.5) Interest expense and amortization of debt discounts and fees (34.3) (36.3) (69.5) (72.7) Stock-based compensation (13.6) (15.6) (22.9) (23.5) Gain (loss) on disposal or impairment of assets(4) 3.0 (0.8) (10.7) (1.5) 154.0 124.3 298.5 244.4 Items not indicative of ongoing operating performance: State regulatory change impact on noncontrolling interests(3) — 2.2 — 2.2 Change in fair market value of equity securities (0.4) (1.1) (0.1) (0.6) Asset impairment impact on noncontrolling interests(4) — — 7.3 — Pre-tax income 153.6 125.4 305.7 246.0 Income tax expense (38.3) (32.8) (76.6) (64.7) Income from continuing operations* $ 115.3 $ 92.6 $ 229.1 $ 181.3 Diluted shares (see page 24) 102.0 101.1 102.1 101.0 Diluted earnings per share* $ 1.13 $ 0.91 $ 2.24 $ 1.79 * Earnings per share are determined using income from continuing operations attributable to Encompass Health. Reconciliations to GAAP provided on pages 25-32. Refer to pages 33-34 for end notes.

 
Encompass Health 9 Adjusted earnings per share(5) Refer to pages 33-34 for end notes. Q2 6 Months 2024 2023 2024 2023 Diluted earnings per share, as reported $ 1.13 $ 0.91 $ 2.24 $ 1.79 Adjustments, net of tax: Asset impairment impact(4) — — 0.02 — Income tax adjustments (0.02) — (0.03) — State regulatory change impact(3) — 0.03 — 0.03 Change in fair market value of equity securities — 0.01 — — Adjusted earnings per share* $ 1.11 $ 0.95 $ 2.23 $ 1.83 u Adjusted earnings per share removes from GAAP earnings per share the impact of items the Company believes are not indicative of its ongoing operating performance. * Adjusted EPS may not sum due to rounding. See complete calculations of adjusted earnings per share on pages 28-32.

 
Encompass Health 10 $282.9 $66.2 $(4.2) $3.4 $(45.1) $6.9 $310.1 Adjusted free cash flow 6 mos. 2023 Adjusted EBITDA Working capital and other Cash interest payments Cash tax payments, net of refunds Maintenance capital expenditures Adjusted free cash flow 6 mos. 2024 2024 YTD Adjusted free cash flow(6) Reconciliations to GAAP provided on pages 25-32. Refer to pages 33-34 for end notes. ($ in millions)

 
Encompass Health 11 2024 Guidance - Updated as of August 5, 2024 Previous Guidance Updated Guidance ($ in millions, except per share data) Net Operating Revenue $5,250 to $5,325 $5,275 to $5,350 Adjusted EBITDA(2) $1,030 to $1,065 $1,040 to $1,075 Adjusted earnings per share from continuing operations attributable to Encompass Health(5) $3.86 to $4.11 $3.97 to $4.22 Refer to pages 33-34 for end notes.

 
Encompass Health 12 2024 Guidance considerations u Pricing Ÿ Medicare pricing increase of 3.3% for Q3 and Q4 Ÿ Managed Care pricing increase of 2% to 3% Ÿ Bad debt reserves of 2.4% to 2.6% of revenue u Labor Ÿ SWB per FTE (including contract labor, sign-on and shift bonuses) increase of 4% to 5% u Capacity additions Ÿ 6 de novo hospitals with 280 beds ü De novo net pre-opening and ramp-up costs of $15 million to $18 million (inclusive of costs associated with 2025 de novos incurred in 2024) Ÿ 1 40-bed satellite hospital (accounted for in bed additions) Ÿ Approximately 110 beds to existing hospitals u Corporate Ÿ 2H Adjusted EBITDA impact of approximately $6 million ü Enterprise system conversion (Oracle Fusion) costs of approximately $2.5 million ü Addition of our existing Augusta, Georgia hospital to Piedmont joint venture increasing income attributable to noncontrolling interests (NCI) by approximately $3.5 million Ÿ Tax rate of approximately 26% Ÿ Diluted share count of approximately 102 million shares

 
Encompass Health 13 Adjusted free cash flow(6) assumptions Certain cash flow items ($ in millions) 6 Months  2024 Actuals 2023 Actuals 2024 Assumptions Cash interest payments (net of amortization of debt discounts and fees) $64.6 $134.0 ~ $130 Cash payments for income taxes, net of refunds $92.0 $106.6 $150 to $170 Working capital and other $(9.5) $(12.1) $30 to $50 Maintenance CAPEX $87.6 $216.9 $185 to $195 Adjusted free cash flow $310.1 $525.7 $495 to $580 Increased cash taxes due to higher net income and phase-out of bonus depreciation; 2023 cash taxes benefited from $11 million overpayment in 2022 applied to 2023 Increased working capital due to growth in accounts receivable and the timing of payroll and payroll tax liabilities Reconciliations to GAAP provided on pages 25-32. Refer to pages 33-34 for end notes.

 
Encompass Health 14 Uses of free cash flow ($ in millions) 6 Months 2024 Actuals 2023 Actuals 2024 Assumptions Growth in core business IRF bed expansions $41.7 $41.8 $105 to $115 New IRFs - De novos 164.0 321.6 290 to 300 - Replacement IRFs and other(7) 3.0 24.2 TBD $208.7 $387.6 $395 to $415 Debt reduction Debt redemptions (borrowings), net ($4.0) $54.4 TBD Shareholder distributions Cash dividends on common stock $30.8 $60.4 ~ $63 Common stock repurchases $16.8 $— TBD Refer to pages 33-34 for end notes. Ÿ Increased common stock repurchase authorization to $500 million as of July 24, 2024(1) Ÿ Issued notice of redemption for $150 million of 5.75% Senior Notes due 2025 with a settlement date of August 15, 2024

 
Appendix

 
Encompass Health 16 ~39,400 employees Rehabilitation hospitals “IRFs” De novos under development* * De novos under development - previously announced de novo hospitals under development as of July 29, 2024 ** IRFs under development include de novo and remote and satellite locations(8) † Based on 2023 and 2022 data Refer to pages 33-34 for end notes. Encompass Health Largest owner and operator of rehabilitation hospitals Company profile as of 06/30/24 163 Rehabilitation hospitals “IRFs” 64 are joint ventures 18 37 IRFs under development** States and Puerto Rico 25% of Licensed beds † 34% of Medicare patients served † Key statistics trailing four quarters ~239,000 patient discharges ~$5.1 Billion in revenue Top Places to Work in Healthcare

 
Encompass Health 17 Growth targets, fundamentals and value drivers u 2023 - 2027 Growth targets Ÿ 6 to 10 de novos per year Ÿ 80 to 120 bed additions per year Ÿ 6% to 8% discharge CAGR u Large, under penetrated, and growing inpatient rehabilitation market Ÿ Large addressable market indicated by low conversion rate of presumptively eligible inpatient rehabilitation patients Ÿ Favorable demographics driving increased demand for rehabilitation services Ÿ Unparalleled clinical expertise for treating inpatient rehabilitation conditions with consistent delivery of high-quality, cost-effective care Ÿ De novo and bed addition strategy delivers attractive financial returns Ÿ Cash flow and capital availability to fund capacity additions Ÿ Fragmented sector presents unit acquisition and joint venture opportunities Ÿ Significant barriers to entry and economies of scale Ÿ Resilient business model with focus on non-discretionary conditions occurring predominantly in an aging population u Shareholder distributions Ÿ Cash dividend (currently $0.17 per share per quarter) Ÿ $500 million share repurchase authorization as of July 24, 2024(1) Refer to pages 33-34 for end notes.

 
Encompass Health 18 Inpatient Rehabilitation Hospitals opened or under development Joint venture Expected open date # of new beds 2024 2025 2026 De novos* Kissimmee, FL 50 — — Atlanta, GA ü 40 — — Louisville, KY ü 40 — — 1 Johnston, RI 3Q24 50 — — 2 Fort Mill, SC 3Q24 39 — — 3 Houston, TX 4Q24 61 — — 4 Athens, GA ü 1Q25 — 40 — 5 Fort Myers, FL ü 2Q25 — 60 — 6 Daytona Beach, FL 2Q25 — 50 — 7 St. Petersburg, FL 3Q25 — 50 — 8 Lake Worth, FL 3Q25 — 50 — 9 Danbury, CT 3Q25 — 40 — 10 Amarillo, TX — — 50 11 Concordville, PA — — 50 12 Norristown, PA — — 50 13 Loganville, GA ü — — 40 14 Irmo, SC — — 50 15 Palm Beach Gardens, FL — — 50 16 Avondale, AZ — — 60 17 San Antonio, TX — — 50 Remote and satellite(8)* Ballwin, MO (Town & Country) ü 40 — — 18 Wildwood, FL (in The Villages, FL) 4Q25 — 50 — Other bed additions ~110 ~80 ~80 *All dates are tentative and subject to change 430 420 480 Development activity 2Q 2024 Development activity highlights uOpened de novos # of beds JV Ÿ Kissimmee, FL 50 Ÿ Atlanta, GA 40 ü Ÿ Louisville, KY 40 ü Opened satellite # of beds JV Ÿ Ballwin, MO (Town and Country) 40 ü Beds added to existing hospitals 24 uAnnounced de novo # of beds JV Ÿ San Antonio, TX 50 IRF development projects announced and underway** 18 ** IRFs under development include de novo and remote and satellite locations(8) Refer to pages 33-34 for end notes.

 
Encompass Health 19 2023 2024 2025 2026 2027 2028 2029 2030 2031 * This chart does not include ~$329 of finance lease obligations or ~$77 of other notes payable. See the debt schedule on page 20. Debt maturity profile - face value $350 Senior Notes 5.75% ($ in millions) Revolver capacity $800 Senior Notes 4.75% $800 Senior Notes 4.5% Revolver As of June 30, 2024* $964 Available $— Drawn + $36 reserved for LCs Callable at par Callable beginning February 2025Callable at 101.125 $400 Senior Notes 4.625% Callable beginning April 2026 Issued notice of redemption for $150 million of 5.75% Senior Notes due 2025 with a settlement date of August 15, 2024

 
Encompass Health 20 Debt schedule Change in June 30, December 31, Debt vs. ($ in millions) 2024 2023 YE 2023 Advances under $1 billion revolving credit facility $ — $ — $ — Bonds Payable: 5.75% Senior Notes due 2025 349.0 348.5 0.5 4.50% Senior Notes due 2028 786.7 785.0 1.7 4.75% Senior Notes due 2030 782.8 781.5 1.3 4.625% Senior Notes due 2031 392.0 391.5 0.5 Other notes payable 76.7 66.0 10.7 Finance lease obligations 329.4 340.1 (10.7) Long-term debt $ 2,716.6 $ 2,712.6 $ 4.0 Debt to Adjusted EBITDA 2.6 x 2.8 x Leverage net of cash and cash equivalents 2.5 x 2.7 x Reconciliations to GAAP provided on pages 25-32. The leverage ratio for 2Q24 stated in terms of the most comparable GAAP measurement would be Debt to Net cash provided by operating activities: 3.1x The leverage ratio for 2023 stated in terms of the most comparable GAAP measurement would be Debt to Net cash provided by operating activities: 3.2x

 
Encompass Health 21 0.0% 5.0% 10.0% 15.0% 20.0% New-store/same-store growth Shreveport, LA (40 beds) Waco, TX (40 beds) Greenville, SC (40 beds) Pensacola, FL (40 beds) Discharges Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 New store 2.0% 3.6% 3.8% 3.3% 3.4% 3.1% 3.5% 3.6% 3.0% 3.0% 3.3% 1.9% Same store(9) 6.7% 6.0% 3.8% 1.6% 4.1% 4.2% 5.9% 6.2% 4.3% 5.3% 6.7% 4.8% Total by quarter 8.7% 9.6% 7.6% 4.9% 7.5% 7.3% 9.4% 9.8% 7.3% 8.3% 10.0% 6.7% Total by year 8.7% 6.8% 8.7% Same store by year(9) 6.2% 3.1% 4.8% Shiloh, IL (40 beds) St. Augustine, FL (40 beds) Libertyville, IL (60 beds) Henry County, GA (50 beds) Moline, IL (40 beds) Naples, FL (50 beds) Grand Forks, ND (40 beds) Lakeland, FL (50 beds) Cape Coral, FL (40 beds) Jacksonville, FL (50 beds) Knoxville, TN (73 beds) Owasso, OK (40 beds) Clermont, FL (50 beds) Bowie, MD (60 beds) Columbus, GA (40 beds) Prosper, TX (40 beds) Fitchburg, WI (56 beds) Kissimmee, FL (50 beds) Atlanta, GA (40 beds) Louisville, KY (40 beds) Refer to pages 33-34 for end notes.

 
Encompass Health 22 Payment sources (percent of revenues) Q2 6 Months Full Year 2024 2023 2024 2023 2023 Medicare 64.7 % 64.4 % 64.8 % 64.7 % 65.0 % Medicare Advantage 17.2 % 16.7 % 17.1 % 16.4 % 16.2 % Managed care 10.7 % 11.2 % 10.7 % 11.1 % 11.1 % Medicaid 3.3 % 4.1 % 3.4 % 4.1 % 4.0 % Other third-party payors 0.8 % 0.9 % 0.8 % 0.9 % 0.9 % Workers’ compensation 0.5 % 0.6 % 0.5 % 0.6 % 0.5 % Patients 0.3 % 0.3 % 0.3 % 0.3 % 0.3 % Other income 2.5 % 1.8 % 2.4 % 1.9 % 2.0 % Total 100.0 % 100.0 % 100.0 % 100.0 % 100.0 %

 
Encompass Health 23 Operational metrics Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2024 2024 2023 2023 2023 2023 2023 Net patient revenue-inpatient $ 1,265.5 $ 1,282.7 $ 1,216.8 $ 1,180.5 $ 1,162.3 $ 1,134.2 $ 4,693.8 Net patient revenue-outpatient and other revenues 35.7 33.3 30.0 26.4 24.8 26.2 107.4 Net operating revenues $ 1,301.2 $ 1,316.0 $ 1,246.8 $ 1,206.9 $ 1,187.1 $ 1,160.4 $ 4,801.2 Discharges(10) 60,833 61,111 59,247 57,665 57,011 55,557 229,480 Net patient revenue per discharge $ 20,803 $ 20,990 $ 20,538 $ 20,472 $ 20,387 $ 20,415 $ 20,454 Outpatient visits 29,312 29,744 29,627 28,604 30,752 31,852 120,835 Average length of stay 12.2 12.3 12.3 12.4 12.3 12.5 12.4 Occupancy % 74.5 % 76.7 % 73.4 % 72.8 % 72.4 % 73.4 % 72.1 % # of licensed beds 10,948 10,781 10,778 10,677 10,611 10,510 10,778 Occupied beds 8,156 8,269 7,911 7,773 7,682 7,714 7,771 Full-time equivalents (FTEs) - internal 27,297 27,209 26,713 26,112 25,453 25,122 25,850 Contract labor FTEs 450 434 378 388 476 459 425 Total FTEs(11) 27,747 27,643 27,091 26,500 25,929 25,581 26,275 EPOB(12) 3.40 3.34 3.42 3.41 3.38 3.32 3.38 Refer to pages 33-34 for end notes.

 
Encompass Health 24 Share information Weighted Average for the Period Q2 6 Months Full Year (in millions) 2024 2023 2024 2023 2023 2022 2021 Basic shares outstanding 99.9 99.5 99.9 99.5 99.5 99.2 99.0 Restricted stock awards, dilutive stock options, and restricted stock units 2.1 1.6 2.2 1.5 1.8 1.2 1.2 Diluted shares outstanding 102.0 101.1 102.1 101.0 101.3 100.4 100.2 End of Period Q2 6 Months Full Year (in millions) 2024 2023 2024 2023 2023 2022 2021 Basic shares outstanding 100.7 100.2 100.7 100.2 100.3 99.8 99.5

 
Encompass Health 25 Net cash provided by operating activities reconciled to Adjusted EBITDA(2) Q2 6 Months Full Year ($ in millions) 2024 2023 2024 2023 2023 Net cash provided by operating activities $ 217.4 $ 206.7 $ 456.2 $ 434.6 $ 850.8 Interest expense and amortization of debt discounts and fees 34.3 36.3 69.5 72.7 143.5 (Loss) gain on sale of investments, excluding impairments (0.1) 0.1 1.2 1.8 4.6 Equity in net income of nonconsolidated affiliates 1.4 0.9 2.1 1.3 3.2 Net income attributable to noncontrolling interests in continuing operations (32.4) (25.8) (58.7) (51.4) (111.0) Amortization of debt-related items (2.5) (2.4) (4.9) (4.7) (9.5) Distributions from nonconsolidated affiliates (1.2) (0.1) (2.0) (0.2) (1.6) Current portion of income tax expense 40.6 36.5 72.4 64.4 128.3 Change in assets and liabilities 11.8 (3.5) 13.4 (41.4) (50.3) Cash used in operating activities of discontinued operations 2.0 1.6 2.7 2.9 16.0 State regulatory change impact on noncontrolling interests(3) — (2.2) — (2.2) (2.2) Asset impairment impact on noncontrolling interests(4) — — (7.3) — — Change in fair market value of equity securities 0.4 1.1 0.1 0.6 (0.7) Other 0.1 0.4 0.1 0.2 — Adjusted EBITDA $ 271.8 $ 249.6 $ 544.8 $ 478.6 $ 971.1 Refer to pages 33-34 for end notes.

 
Encompass Health 26 Reconciliation of net income to Adjusted EBITDA(2) Q2 6 Months Full Year ($ in millions) 2024 2023 2024 2023 2023 Net income $ 146.5 $ 117.2 $ 285.3 $ 230.5 $ 463.0 Loss from discontinued operations, net of tax, attributable to Encompass Health 1.2 1.2 2.5 2.2 12.0 Net income attributable to noncontrolling interests included in continuing operations (32.4) (25.8) (58.7) (51.4) (111.0) Provision for income tax expense 38.3 32.8 76.6 64.7 132.2 Interest expense and amortization of debt discounts and fees 34.3 36.3 69.5 72.7 143.5 Depreciation and amortization(3) 72.9 72.6 143.2 136.5 273.9 (Gain) loss on disposal or impairment of assets(4) (3.0) 0.8 10.7 1.5 9.8 Stock-based compensation 13.6 15.6 22.9 23.5 50.6 State regulatory change impact on noncontrolling interests(3) — (2.2) — (2.2) (2.2) Change in fair market value of equity securities 0.4 1.1 0.1 0.6 (0.7) Asset impairment impact on noncontrolling interests(4) — — (7.3) — — Adjusted EBITDA $ 271.8 $ 249.6 $ 544.8 $ 478.6 $ 971.1 Refer to pages 33-34 for end notes.

 
Encompass Health 27 Reconciliation of net cash provided by operating activities to adjusted free cash flow(6) Q2 6 Months Full Year ($ in millions) 2024 2023 2024 2023 2023 Net cash provided by operating activities $ 217.4 $ 206.7 $ 456.2 $ 434.6 $ 850.8 Impact of discontinued operations 2.0 1.6 2.7 2.9 16.0 Net cash provided by operating activities of continuing operations 219.4 208.3 458.9 437.5 866.8 Capital expenditures for maintenance (48.9) (56.7) (87.6) (94.5) (216.9) Distributions paid to noncontrolling interests of consolidated affiliates (27.8) (27.6) (52.5) (59.4) (114.7) Items not indicative of ongoing operating performance: Transaction costs and related liabilities (0.2) 0.2 (8.7) (0.7) (9.5) Adjusted free cash flow $ 142.5 $ 124.2 $ 310.1 $ 282.9 $ 525.7 Cash dividends on common stock $ 14.9 $ 14.9 $ 30.8 $ 30.5 $ 60.4 Refer to pages 33-34 for end notes.

 
Encompass Health 28 Adjusted EPS(5) - Q2 2024 For the Three Months Ended June 30, 2024 Adjustments As Reported Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 271.8 $ — $ — $ 271.8 Depreciation and amortization (72.9) — — (72.9) Interest expense and amortization of debt discounts and fees (34.3) — — (34.3) Stock-based compensation (13.6) — — (13.6) Gain on disposal or impairment of assets 3.0 — — 3.0 Change in fair market value of equity securities (0.4) — 0.4 — Income from continuing operations before income tax expense 153.6 — 0.4 154.0 Provision for income tax expense (38.3) (2.4) (0.1) (40.8) Income from continuing operations attributable to Encompass Health $ 115.3 $ (2.4) $ 0.3 $ 113.2 Diluted earnings per share from continuing operations* $ 1.13 $ (0.02) $ — $ 1.11 Diluted shares used in calculation 102.0 * Adjusted EPS may not sum across due to rounding. Refer to pages 33-34 for end notes.

 
Encompass Health 29 For the Three Months Ended June 30, 2023 Adjustments As Reported State Regulatory Change Impact Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 249.6 $ — $ — $ — $ 249.6 Depreciation and amortization(3) (72.6) 6.1 — — (66.5) Interest expense and amortization of debt discounts and fees (36.3) — — — (36.3) Stock-based compensation (15.6) — — — (15.6) Loss on disposal or impairment of assets (0.8) — — — (0.8) State regulatory change impact on noncontrolling interests(3) 2.2 (2.2) — — — Change in fair market value of equity securities (1.1) — — 1.1 — Income from continuing operations before income tax expense 125.4 3.9 — 1.1 130.4 Provision for income tax expense (32.8) (1.0) 0.1 (0.3) (34.0) Income from continuing operations attributable to Encompass Health $ 92.6 $ 2.9 $ 0.1 $ 0.8 $ 96.4 Diluted earnings per share from continuing operations* $ 0.91 $ 0.03 $ — $ 0.01 $ 0.95 Diluted shares used in calculation 101.1 Adjusted EPS(5) - Q2 2023 * Adjusted EPS may not sum across due to rounding. Refer to pages 33-34 for end notes.

 
Encompass Health 30 Adjusted EPS(5) - YTD Q2 2024 For the Six Months Ended June 30, 2024 Adjustments As Reported Asset Impairment Impact Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 544.8 $ — $ — $ — $ 544.8 Depreciation and amortization (143.2) — — — (143.2) Interest expense and amortization of debt discounts and fees (69.5) — — — (69.5) Stock-based compensation (22.9) — — — (22.9) Loss on disposal or impairment of assets(4) (10.7) 10.4 — — (0.3) Change in fair market value of equity securities (0.1) — — 0.1 — Asset impairment impact on noncontrolling interests(4) 7.3 (7.3) — — — Income from continuing operations before income tax expense 305.7 3.1 — 0.1 308.9 Provision for income tax expense (76.6) (1.3) (3.0) — (80.9) Income from continuing operations attributable to Encompass Health $ 229.1 $ 1.8 $ (3.0) $ 0.1 $ 228.0 Diluted earnings per share from continuing operations* $ 2.24 $ 0.02 $ (0.03) $ — $ 2.23 Diluted shares used in calculation 102.1 * Adjusted EPS may not sum across due to rounding. Refer to pages 33-34 for end notes.

 
Encompass Health 31 For the Six Months Ended June 30, 2023 Adjustments As Reported State Regulatory Change Impact Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 478.6 $ — $ — $ — $ 478.6 Depreciation and amortization(3) (136.5) 6.1 — — (130.4) Interest expense and amortization of debt discounts and fees (72.7) — — — (72.7) Stock-based compensation (23.5) — — — (23.5) Loss on disposal or impairment of assets (1.5) — — — (1.5) State regulatory change impact on noncontrolling interests(3) 2.2 (2.2) — — — Change in fair market value of equity securities (0.6) — — 0.6 — Income from continuing operations before income tax expense 246.0 3.9 — 0.6 250.5 Provision for income tax expense (64.7) (1.0) 0.4 (0.2) (65.5) Income from continuing operations attributable to Encompass Health $ 181.3 $ 2.9 $ 0.4 $ 0.4 $ 185.0 Diluted earnings per share from continuing operations* $ 1.79 $ 0.03 $ — $ — $ 1.83 Diluted shares used in calculation 101.0 Adjusted EPS(5) - YTD Q2 2023 * Adjusted EPS may not sum across due to rounding. Refer to pages 33-34 for end notes.

 
Encompass Health 32 Adjusted EPS(5) - 2023 For the Year Ended December 31, 2023 Adjustments As Reported State Regulatory Change Impact Income Tax Adjustments Change in Fair Market Value of Equity Securities As Adjusted ($ in millions, except per share amounts) Adjusted EBITDA $ 971.1 $ — $ — $ — $ 971.1 Depreciation and amortization(3) (273.9) 6.1 — — (267.8) Interest expense and amortization of debt discounts and fees (143.5) — — — (143.5) Stock-based compensation (50.6) — — — (50.6) Loss on disposal or impairment of assets (9.8) — — — (9.8) State regulatory change impact on noncontrolling interests(3) 2.2 (2.2) — — — Change in fair market value of equity securities 0.7 — — (0.7) — Income from continuing operations before income tax expense 496.2 3.9 — (0.7) 499.4 Provision for income tax expense (132.2) (1.0) 2.8 0.2 (130.2) Income from continuing operations attributable to Encompass Health $ 364.0 $ 2.9 $ 2.8 $ (0.5) $ 369.2 Diluted earnings per share from continuing operations* $ 3.59 $ 0.03 $ 0.03 $ — $ 3.64 Diluted shares used in calculation 101.3 * Adjusted EPS may not sum across due to rounding. Refer to pages 33-34 for end notes.

 
Encompass Health 33 End notes Reconciliations to GAAP provided on pages 25-32. (1) On Oct. 28, 2013, the Company announced its board of directors authorized the repurchase of up to $200 million of its common stock. On Feb. 14, 2014, the Company's board approved an increase in this common stock repurchase authorization from $200 million to $250 million. As of June 30, 2018, the remaining repurchase authorization was approximately $58 million. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $250 million. As of June 30, 2024, the remaining repurchase authorization was approximately $181 million. On July 24, 2024, the Company’s board approved resetting the aggregate common stock repurchase authorization to $500 million. (2) Adjusted EBITDA is a non-GAAP financial measure. The Company’s leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future the Company may incur expenses similar to the adjustments set forth. (3) In May of 2023, the governor of South Carolina signed into law S.164, which repealed the requirement of certain healthcare providers to obtain and/or maintain a certificate of need (“CON”). As a results of this repeal, in Q2 2023 we accelerated amortization of approximately $6 million in remaining carrying value of our South Carolina CON assets, increasing depreciation and amortization expense by approximately $6 million and reducing noncontrolling interest in continuing operations by approximately $2 million (related to our joint venture partner’s share of income at one impacted location). The impact of these adjustments have been excluded from the calculation of Adjusted EBITDA and adjusted earnings per share in the second quarter of 2023 given the non- recurring nature of the CON repeal (Florida is the only other state in recent history to repeal its CON law) is not indicative of ongoing operating performance. (4) In January 2024, we received notice that our joint venture partner, Hospital Sisters Health System, intended to close its acute-care hospital, Sacred Heart Hospital in Eau Claire, WI, in which our joint venture inpatient rehabilitation hospital is located. We closed that joint venture hospital in February 2024 and incurred a one-time impairment charge of $10.4 million. The impact to net income attributable to Encompass Health during the six months ended June 30, 2024 resulting from the impairment was $1.8 million after reductions for net income attributable to noncontrolling interests of $7.3 million and the provision for income tax expense of $1.3 million.

 
Encompass Health 34 End notes (continued) (5) The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”), which is a non-GAAP measure. The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements, professional fees - accounting, tax, and legal, mark-to-market adjustments for stock appreciation rights, gains or losses related to hedging and equity instruments, loss on early extinguishment of debt, adjustments to its income tax provision (such as valuation allowance adjustments, settlements of income tax claims and windfall tax benefits), items related to corporate and facility restructurings, and certain other items deemed to be non-indicative of ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company's ongoing operating performance. Accordingly, they can complicate comparisons of the Company's results of operations across periods and comparisons of the Company's results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. (6) The definition of adjusted free cash flow, which is a non-GAAP measure, is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, distributions to noncontrolling interests, and certain items deemed to be non-indicative of ongoing operating performance. Common stock dividends are not included in the calculation of adjusted free cash flow. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. (7) In September 2023, we purchased our Treasure Coast hospital (Vero Beach, Florida) real estate from Ocean Health Associates, LTD. (“Ocean Health”) for $21.4 million. Prior to the purchase, we leased the real estate from Ocean Health. The $21.4 million payment is included in Principal payments under finance lease obligations on the consolidated statement of cash flows for the twelve months ended December 31, 2023. (8) Our inpatient rehabilitation hospitals (“IRFs”) may operate one or more satellite and/or remote locations. Satellite and remote locations are located proximate to one of our existing IRFs but do not have a separate Medicare provider number. As such, they are considered a bed addition, are included in same store results from the day of opening, and are not included in our count of total open hospitals. As of June 30, 2024, we operate 11 satellite and remote locations. (9) Same-store comparisons are calculated based on hospitals open throughout both the full current periods and prior periods presented. These comparisons include the financial results of market consolidation transactions and capacity expansions (including the addition of satellite and remote hospitals) in existing markets. (10) Represents discharges from 163 consolidated hospitals in Q2 2024; 160 consolidated hospitals in Q1 2024; 161 consolidated hospitals in Q4 2023; 159 consolidated hospitals in Q3 2023; 158 consolidated hospitals in Q2 2023; and 156 consolidated hospitals in Q1 2023. (11) Total full-time equivalents included in the table represent Encompass Health employees who participate in or support the operations of our hospitals and include full-time equivalents related to contract labor. (12) Employees per occupied bed, or “EPOB,” is calculated by dividing the number of total full-time equivalents, including full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. Reconciliations to GAAP provided on pages 25-32.